Invesco Nasdaq Biotechnology ETF (IBBQ)
| Assets | $21.84M |
| NAV | $19.16 |
| Expense Ratio | 0.19% |
| PE Ratio | 72.45 |
| Shares Out | 1.14M |
| Dividend (ttm) | $0.22 |
| Dividend Yield | 1.13% |
| Ex-Dividend Date | Sep 19, 2022 |
| 1-Year Return | -23.82% |
| Volume | 3,171 |
| Open | 19.48 |
| Previous Close | 19.16 |
| Day's Range | 19.48 - 19.68 |
| 52-Week Low | 16.73 |
| 52-Week High | 26.15 |
| Beta | -1.22 |
| Holdings | 365 |
| Inception Date | Jun 11, 2021 |
About IBBQ
The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq compiles the underlying index, which is a modified market capitalization weighted index that is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The index may include securities of large-, mid- and small-capitalization companies. The fund is non-diversified.
Top 10 Holdings
51.45% of assets| Name | Symbol | Weight |
|---|---|---|
| Gilead Sciences | GILD | 7.98% |
| Amgen | AMGN | 7.70% |
| Vertex Pharmaceuticals | VRTX | 7.68% |
| Regeneron Pharmaceuticals | REGN | 7.64% |
| Moderna | MRNA | 4.79% |
| Biogen | BIIB | 4.01% |
| AstraZeneca | AZN | 3.46% |
| Illumina | ILMN | 3.10% |
| Seagen | SGEN | 2.61% |
| Alnylam Pharmaceuticals | ALNY | 2.49% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| 2022-09-19 | $0.03769 | 2022-09-23 |
| 2022-06-21 | $0.04264 | 2022-06-30 |
| 2022-03-21 | $0.03778 | 2022-03-31 |
| 2021-12-20 | $0.10511 | 2021-12-31 |
| 2021-09-20 | $0.04324 | 2021-09-30 |
News
Invesco's Rene Reyna on Biotech's Rally and the Potential for Future Growth
Biotech has had a strong rally since June, when fortune for the sector abruptly pivoted after months of underperformance. The sector peaked in early 2021 but struggled to continue the momentum, despit...
Moderna Q2 Earnings, Buyback Plans Lift Biotech ETFs
Moderna Inc (NasdaqGS: MRNA) shares surged Wednesday, lifting biotechnology sector-related exchange traded funds, after the pharmaceutical company revealed better-than-expected profit and revenue in its...
Pfizer Biohaven Acquisition Sparks Hope of More Biotech M&A
Earlier this week, Pfizer (NYSE:PFE) announced plans to acquire Biohaven Pharmaceutical (NASDAQ:BHVN) for $11.6 billion, sparking hopes of more biotechnology consolidation activity to come. Pfizer is pa...
Battered Biotech Space Now Unbelievably Inexpensive
After disappointing in 2021, biotechnology stocks and exchange traded funds are getting shellacked this year as growth stocks fall out of favor due to rising interest rates. As experienced biotech inves...
Biotech ETFs Muddled Despite Amgen Strength
Biotechnology sector-specific exchange traded funds were flat after Amgen (NasdaqGS: AMGN) provided a mixed earnings report but announced that it will return value to investors through greater share buy...
Cap-Weighting Crucial When Indexing Biotech
The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams because their new drug or treatment is still in developm...
Biotech Firms Partner to Advance Therapeutic Medicine
Although biotechnology stocks have been lackluster for the past year, the industry is gaining increased attention of late, not just for the role it's played in combatting the COVID-19 pandemic, but also...
An ETF to Capture Promising Biotech Innovators
Innovative biotechnology companies are coming out with novel treatments in the healthcare industry. Investors can also capture the ongoing innovations in the biotech sector through a targeted exchange t...
Biotech Stocks and ETFs Can Get Their Grooves Back
As is now widely documented, biotechnology stocks and exchange traded funds endured a rough 2021. Compounding those woes is the fact that investors were caught off guard by last year's lethargy because ...
Expect More Biotech Consolidation Activity in 2022
The biotechnology industry is often a hotbed of mergers and acquisitions speculation. Announced deals are a different matter altogether.
Moderna's Omicron Booster Strategy Lifts Biotechnology ETFs
Moderna (NasdaqGS: MRNA) jumped on Monday after announcing that a higher dosage booster of its vaccine could help mitigate COVID-19 Omicron risks before a tailor-made shot is finalized, lifting biotechn...
Position for Biotech Rebound With Quality Names
Broadly speaking, 2021 hasn't been kind to biotechnology stocks and exchange traded funds, but some market participants remain optimistic regarding a rebound for these previously beloved assets. One way...
An ETF to Watch for Amidst the Vaccine Push
While Covid-19 variants on the rise, the push for more vaccinations make the Invesco Nasdaq Biotechnology ETF (IBBQ) an ETF to watch. As Covid cases experience a resurgence, more companies are mandating...
New Biotechnology ETF Could Be a Stellar Second Half Idea
The Invesco Nasdaq Biotechnology ETF (IBBQ) is just a few weeks old, but even with that rookie status, it could be a stellar second half idea. On the back of the Food and Drug Administration (FDA) condi...
A Biotech ETF to Track Nasdaq's Industry-Setting Benchmark
As investors consider the regulatory, scientific, and demographic factors driving today's growth in biotechnology industry, they can look to the Nasdaq Biotechnology Index's methodology and one related ...
The Biotech Trek: A Short History from 1993 to 2021
The Nasdaq Biotechnology Index (NBI) launched in 1993, when the industry was still in the midst of the original “biotech revolution.” Since then, its constituent basket has swelled from roughly 100 comp...